Keyphrases
Clinical Trials
100%
Targeted Treatment
100%
Bevacizumab
80%
Cisplatin
60%
Targeted Agents
40%
Pemetrexed
40%
Chemotherapy
20%
Tyrosine Kinase Inhibitor
20%
Response Rate
20%
Clinical Benefit
20%
Second-line Treatment
20%
Disease Control
20%
All Clinical Trials
20%
MEDLINE
20%
Sunitinib
20%
PubMed
20%
Tumor Biology
20%
Aggressive Tumor
20%
Partial Response
20%
Poor Prognosis
20%
Induced Response
20%
Phase II Trial
20%
Gemcitabine
20%
Stable Disease
20%
Disease Stabilization
20%
Medicine and Dentistry
Mesothelioma
100%
Clinical Trial
100%
Targeted Therapy
100%
Bevacizumab
80%
Diseases
60%
Cisplatin
60%
Neoplasm
20%
Sunitinib
20%
Tyrosine-Kinase Inhibitor
20%
Tumor Biology
20%
Gemcitabine
20%
Phase II Trials
20%
Arm
20%
Pharmacology, Toxicology and Pharmaceutical Science
Mesothelioma
100%
Clinical Trial
100%
Bevacizumab
80%
Diseases
60%
Cisplatin
60%
Pemetrexed
40%
Neoplasm
40%
Gemcitabine
20%
Phase II Trials
20%
Protein Tyrosine Kinase Inhibitor
20%
Sunitinib
20%
Chemotherapy
20%